TORNTPHARMNSETorrent Pharmaceuticals Limited· PharmaceuticalsMediumNeutral
Announced Mon, 30 Jun · 13:18 IST

Torrent Pharmaceuticals Limited has informed the Exchange about Investor Presentation

Promoter Disclosed Acquisition PlansInvestor Communications View source PDF

TORNTPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Torrent Pharma has shared its investor presentation detailing the acquisition of a 46.39% controlling stake in JB Chemicals & Pharmaceuticals at INR 1,600 per share, totalling about INR 11,917 crores. A mandatory open offer for an additional 26% from public shareholders will follow at INR 1,639.18 per share, plus an intent to acquire up to 2.80% from JB Pharma employees. Torrent and JB Pharma will merge, with Torrent as the surviving listed entity, at a swap ratio of 51 Torrent shares for every 100 JB Pharma shares. The deal will lift Torrent's prescription ranking to #5 and secondary sales ranking to #4 in the Indian pharma market. Completion is expected in 15-18 months, subject to CCI, SEBI, stock exchange, and shareholder/creditor approvals.

Likely market impact

This is a major, transformative acquisition that substantially expands Torrent Pharma's domestic market share and therapeutic reach, but the INR 11,917 crore outlay plus open offer will significantly increase debt and dilute existing shareholders. Share price reaction will depend on how the market values the synergy potential versus the leverage and dilution from the share swap.